Kopfbereich

AOP Orphan to implement innovative CRM system in collaboration with IQVIA Austria


AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.

AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. As a specialist in Orphan Diseases, AOP Orphan researches, develops, produces, and distributes innovative solutions in the following therapeutic areas: hematooncology, cardiology and pulmonology, neurology and metabolic diseases. Today AOP Orphan is active at an international level with an export ratio of about 70% and has representative offices in thirteen countries worldwide.

To facilitate continuous excellence within AOP Orphan’s field teams worldwide, the innovative Mobile IntelligenceTM (MI) CRM Tool, developed by leading Life Science Consultants IQVIA, has been selected and, with the support of IQVIA’s Austrian Team, will be tailored to AOP’s specific needs in this area.

About IQVIA (NYSE: IQV)

A leading, global supplier of information, innovative technology solutions and services within the area of commercialization for the healthcare industry and clinical research, IQVIA uses data, technology and scientific methods to support healthcare professionals in identifying better solutions for their customers.

Contact
Mag. Klaus Kutschera
Kutschera Marketing & Sales Consulting
Stella-Klein-Löw-Weg 15, Haus B, 5. Stock, A-1020 Vienna
M: +43 (0) 664 60600 239
E: klaus.kutschera(at)iqvia.com

About AOP Orphan

Dr. Rudolf Widmann established AOP Orphan in Vienna, Austria in 1996 to provide individualized treatment for patients suffering from rare diseases. Being one of Europe’s leading suppliers in this field AOP Orphan has generated a turnover of more than 95mio EUR with an export ratio of around 70% and more than 210 employees. AOP Orphan has thirteen representative offices across the core markets in EU and Middle East, covering international markets via strong distribution partnerships.

Contact
Dr. Miroslaw Lubecki, MBA
Chief Commercial Officer
AOP Orphan Pharmaceuticals AG

Wilhelminenstraße 91/IIf, A-1160 Vienna

T +43 1 503 72 44-24
E: office(at)aoporphan.com